Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Current and future therapies for hepatitis C virus infection: from viral proteins to host targets Hepatitis C virus (HCV) infection is the most important problem across the world. It causes acute and chronic liver infection. Different approaches are in use to inhibit HCV infection, including small organic compounds, siRNA, shRNA and peptide inhibitors. This review article summarizes the current and future therapies for HCV infection. PubMed and Google Scholar were searched for articles published in English to give an insight into the current inhibitors against this life-threatening virus. HCV NS3/4A protease inhibitors and nucleoside/nucleotide inhibitors of NS5B polymerase are presently in the most progressive stage of clinical development, but they are linked with the development of resistance and viral breakthrough. Boceprevir and telaprevir are the two most important protease inhibitors that have been approved recently for the treatment of HCV infection. These two drugs are now the part of standard-of-care treatment (SOC). There are also many other drugs in phase III of clinical development. When exploring the various host-cell-targeting compounds, the most hopeful results have been demonstrated by cyclophilin inhibitors. The current SOC treatment of HCV infection is Peg-interferon, ribavirin and protease inhibitors (boceprevir or telaprevir). The future treatment of this life-threatening disease must involve combinations of therapies hitting multiple targets of HCV and host factors. It is strongly expected that the near future, treatment of HCV infection will be a combination of direct-acting agents (DAA) without the involvement of interferon to eliminate its side effects. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Virology Springer Journals

Current and future therapies for hepatitis C virus infection: from viral proteins to host targets

Loading next page...
 
/lp/springer_journal/current-and-future-therapies-for-hepatitis-c-virus-infection-from-suDbI9vRUV
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Biomedicine; Virology; Medical Microbiology; Infectious Diseases
ISSN
0304-8608
eISSN
1432-8798
D.O.I.
10.1007/s00705-013-1803-7
Publisher site
See Article on Publisher Site

Abstract

Hepatitis C virus (HCV) infection is the most important problem across the world. It causes acute and chronic liver infection. Different approaches are in use to inhibit HCV infection, including small organic compounds, siRNA, shRNA and peptide inhibitors. This review article summarizes the current and future therapies for HCV infection. PubMed and Google Scholar were searched for articles published in English to give an insight into the current inhibitors against this life-threatening virus. HCV NS3/4A protease inhibitors and nucleoside/nucleotide inhibitors of NS5B polymerase are presently in the most progressive stage of clinical development, but they are linked with the development of resistance and viral breakthrough. Boceprevir and telaprevir are the two most important protease inhibitors that have been approved recently for the treatment of HCV infection. These two drugs are now the part of standard-of-care treatment (SOC). There are also many other drugs in phase III of clinical development. When exploring the various host-cell-targeting compounds, the most hopeful results have been demonstrated by cyclophilin inhibitors. The current SOC treatment of HCV infection is Peg-interferon, ribavirin and protease inhibitors (boceprevir or telaprevir). The future treatment of this life-threatening disease must involve combinations of therapies hitting multiple targets of HCV and host factors. It is strongly expected that the near future, treatment of HCV infection will be a combination of direct-acting agents (DAA) without the involvement of interferon to eliminate its side effects.

Journal

Archives of VirologySpringer Journals

Published: May 1, 2014

References

  • Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
    Kieffer, TL; Sarrazin, C; Miller, JS; Welker, MW; Forestier, N; Reesink, HW; Kwong, AD; Zeuzem, S
  • Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection
    Farnik, H; Lange, CM; Sarrazin, C
  • Resistance to direct antiviral agents in patients with hepatitis C virus infection
    Sarrazin, C; Zeuzem, S
  • Hepatitis C virus genetic variability in patients undergoing antiviral therapy
    Cristina, J; Moreno-del, PM; Moratorio, G
  • Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
    Calland, N; Albecka, A; Belouzard, S
  • HCV NS2 protein inhibits cell proliferation and induces cell cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A expression
    Yang, XJ; Liu, J; Ye, L; Liao, QJ
  • Hepatitis C virus NS2 protein activates cellular cyclic AMP-dependent pathways
    Kim, KM; Kwon, SN; Kang, JI; Lee, SH; Jang, SK; Ahn, BY; Kim, YK
  • Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
    Zeuzem, S; Asselah, T; Angus, P; Zarski, JP; Larrey, D; Müllhaupt, B; Gane, E; Schuchmann, M; Lohse, A; Pol, S; Bronowicki, JP; Roberts, S; Arasteh, K; Zoulim, F; Heim, M; Stern, JO; Kukolj, G; Nehmiz, G; Haefner, C; Boecher, WO
  • Heme Oxygenase-1 Suppresses Hepatitis C Virus Replication and Increases Resistance of Hepatocytes to Oxidant Injury
    Zhu, ZW; Wilson, AT; Mathahs, MM
  • The Heme Oxygenase 1 product biliverdin interferes with Hepatitis C virus replication by increasing antiviral interferon response
    Lehmann, E; EL-Tantawy, WH; Ocker, M
  • Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?
    Zhu, Z; Wilson, AT; Luxon, BA; Brown, KE; Mathahs, MM; Bandyopadhyay, S; McCaffrey, AP; Schmidt, WN
  • Resistance to direct antiviral agents in patients with hepatitis C virus infection
    Sarrazin, C; Zeuzem, S
  • Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory
    Gouttenoire, J; Penin, F; Moradpour, D
  • Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins
    Moradpour, D; Kary, P; Rice, CM; Blum, HE
  • Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
    Gao, M; Nettles, RE; Belema, M; Snyder, LB
  • Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi
    Kong, L; Li, S; Han, X; Xiang, Z; Fang, X; Li, B; Wang, W; Zhong, H; Gao, J; Ye, L
  • Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy
    Shinohara, Y; Imajo, K; Yoneda, M; Tomeno, W; Ogawa, Y; Kirikoshi, H; Funakoshi, K; Ikeda, M; Kato, N; Nakajima, A; Saito, S
  • Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
    Pianko, S; Zeuzem, S; Chuang, WL; Foster, GR; Sarin, SK; Flisiak, R; Lee, CM; Andreone, P; Piratvisuth, T; Shah, S; Sood, A; George, J; Gould, M; Komolmit, P
  • Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
    Rossignol, JF; Kabil, SM; Gohary, Y
  • Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
    Ciancio, A; Andreone, P; Kaiser, S; Mangia, A; Milella, M; Solà, R; Pol, S; Tsianos, E; Rosa, A; Camerini, R; McBeath, R; Rizzetto, M

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off